Page last updated: 2024-08-24

gemcitabine and bosutinib

gemcitabine has been researched along with bosutinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrake, M; Astsaturov, I; Banina, E; Beeharry, N; Deacon, S; Egleston, BL; Hittle, J; Khazak, V; Peterson, JR; Skobeleva, N; Yen, TJ	1

Other Studies

1 other study(ies) available for gemcitabine and bosutinib

Article	Year
Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:14 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; DNA Replication; Dose-Response Relationship, Drug; Doxorubicin; Drug Repositioning; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, SCID; Models, Molecular; Nitriles; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Quinolines; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays	2014

Article

Year

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:14

Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; DNA Replication; Dose-Response Relationship, Drug; Doxorubicin; Drug Repositioning; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, SCID; Models, Molecular; Nitriles; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Quinolines; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays

2014